

5-Phenyl-1,2,4-triazolo[3,4-*b*]benzothiazole

A. Abdul Ajees,<sup>a\*</sup>  
S. Karthikeyan,<sup>b</sup> G. Jayanthi<sup>c</sup> and  
V. T. Ramakrishnan<sup>c</sup>

<sup>a</sup>Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India, <sup>b</sup>Floor 3, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA, 02134, USA, and <sup>c</sup>Department of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India

Correspondence e-mail: alazeez34@yahoo.com

## Key indicators

Single-crystal X-ray study

*T* = 293 K

Mean  $\sigma(\text{C}-\text{C}) = 0.003 \text{ \AA}$

*R* factor = 0.045

w*R* factor = 0.128


Data-to-parameter ratio = 13.0

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title compound,  $\text{C}_{14}\text{H}_9\text{N}_3\text{S}$ , the triazole and benzothiazole moieties are coplanar. The dihedral angle between the fused triazole–benzothiazole fragment and the phenyl ring is  $39.20(5)^\circ$ . The structure is stabilized by  $\text{C}-\text{H}\cdots\text{N}$  intermolecular interactions.

## Comment

The triazole moiety possesses many pharmacological properties, such as acting as an antimicrobial (Habib *et al.*, 1997), antiviral (Ergen *et al.*, 1996), anti-HIV-1 (Invidiata *et al.*, 1996), antifungal, antimycobacterial and anticonvulsant (Gülerman *et al.*, 1997) agent. It is also a highly potent eosinophilia inhibitor (Naito *et al.*, 1996) and is used as fungicide (Crofton, 1996) and herbicide (Tada *et al.*, 1995). Some triazole derivatives have been evaluated for their antibacterial activity against both Gram-positive and Gram-negative bacteria (Bs *et al.*, 1996). Benzothiazoles are extremely important heterocycles from industrial and agricultural points of view. They are also used as antineoplastic agents and show antinociceptive, anti-inflammatory and antitumor activities (Bradshaw *et al.*, 1998; Dögruer *et al.*, 1998). The fused benzothiazole–triazole fragment may have useful medicinal properties. Some Schiff bases derived from thiazole and benzothiazoles (Dash *et al.*, 1980) and several derivatives of the styrylbenzothiazoles have shown biological activity (Cox *et al.*, 1982). In view of these features associated with the benzothiazole and triazole moieties, the structure determination of 5-phenyl-1,2,4-triazolo[3,4-*b*]benzothiazole, (I), incorporating both these units, was undertaken.




Bond distances and angles observed for (I) are similar to those found in the structures of related compounds, namely, 7-methyl-3-(2-methylphenyl)-1,2,4-triazolo[3,4-*b*]benzothiazole and 7-methyl-3-(4-methylphenyl)-1,2,4-triazolo[3,4-*b*]benzothiazole (Puviarasan *et al.*, 1999). The large size of the S atom compared with N results in a reduction of the C1–S1–

Received 28 February 2002

Accepted 4 March 2002

Online 8 March 2002



**Figure 1**  
The molecular structure of (I), showing displacement ellipsoids at the 30% probability level.

C7 angle [89.0 (1)°] compared with the C7—N1—C6 angle [113.5 (2)°] in thiazole ring. This suggests that the S atom might be using unhybridized *p* orbitals for bonding (Muir *et al.*, 1987). As a result of the fusion of the benzothiazole and triazole moieties, the ring-junction endocyclic bond angles are larger than normal values. The title compound is non-planar, with a dihedral angle of 39.20 (5)° between the 1,2,4-triazolo[3,4-*b*]benzothiazole moiety and the phenyl ring. The geometry of the benzothiazole moiety is essentially planar, with no atom deviating from the plane by more than 0.051 (2) Å [ $\chi^2 = 12.6$ ]. The dihedral angle between the mean planes of the rings *A*, *B*, *C* are *A/B* 3.78 (6)°, *A/C* 6.59 (8)° and *B/C* 2.81 (7)°. The structure is stabilized by van der Waals interactions and C—H...N-type intermolecular interactions [H10...N3<sup>i</sup> = 2.61 Å, C10...N3<sup>i</sup> = 3.520 (4) Å and angle at C10—H10...N3<sup>i</sup> = 167.0°; symmetry code: (i)  $-x, -y, -z+1$ ].

## Experimental

The title compound, (I), was obtained from the photolysis of 4-(2-chlorophenyl)-5-phenyl-1,2,4-triazole-3-thione (0.7 g, 0.0024 mol) in absolute methanol (150 ml). It was flushed with nitrogen for 1 h and irradiated for 1.5 h in a thin-film reactor (equipped with one lamp) at 254 nm. After completion of the reaction, the solvent was removed and the residue, on chromatographic purification using an ethyl acetate–petroleum ether mixture (1:6), afforded a yellow solid (m.p. 417–419 K) (Jayanthi *et al.*, 1997). Crystals suitable for an X-ray diffraction study were grown by slow evaporation from ethyl acetate–petroleum ether (1:6) mixture.

### Crystal data

C<sub>14</sub>H<sub>9</sub>N<sub>3</sub>S  
*M<sub>r</sub>* = 251.30  
 Monoclinic, *P*2<sub>1</sub>/*c*  
*a* = 8.702 (1) Å  
*b* = 15.000 (2) Å  
*c* = 9.799 (1) Å  
 $\beta$  = 113.70 (1)°  
*V* = 1171.2 (3) Å<sup>3</sup>  
*Z* = 4

*D<sub>x</sub>* = 1.425 Mg m<sup>-3</sup>  
 Cu *K*α radiation  
 Cell parameters from 25 reflections  
 $\theta$  = 14–30°  
 $\mu$  = 2.31 mm<sup>-1</sup>  
*T* = 293 (2) K  
 Needle, yellow  
 0.35 × 0.13 × 0.10 mm

### Data collection

Enraf–Nonius CAD-4  
 diffractometer  
 $\omega$ -2 $\theta$  scans  
 Absorption correction:  $\psi$  scan  
 (North *et al.*, 1968)  
*T*<sub>min</sub> = 0.924, *T*<sub>max</sub> = 0.998  
 2277 measured reflections  
 2128 independent reflections  
 1936 reflections with *I* > 2σ(*I*)

*R*<sub>int</sub> = 0.031  
 $\theta$ <sub>max</sub> = 69.9°  
*h* = 0 → 10  
*k* = 0 → 18  
*l* = -11 → 10  
 3 standard reflections  
 frequency: 120 min  
 intensity decay: <1%

### Refinement

Refinement on *F*<sup>2</sup>  
*R*[*F*<sup>2</sup> > 2σ(*F*<sup>2</sup>)] = 0.045  
*wR*(*F*<sup>2</sup>) = 0.128  
*S* = 1.09  
 2128 reflections  
 164 parameters  
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0798P)^2 + 0.27P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\max} < 0.001$   
 $\Delta\rho_{\max} = 0.30 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\min} = -0.38 \text{ e \AA}^{-3}$   
 Extinction correction: *SHELXL97*  
 Extinction coefficient: 0.0126 (12)

Data collection: *CAD-4 Software* (Enraf–Nonius, 1989); cell refinement: *SDP* (Frenz, 1978); data reduction: *CAD-4 Software*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPIII* (Farrugia, 1997); software used to prepare material for publication: *PARST97* (Nardelli, 1995).

Thanks are due to the Council of Scientific and Industrial Research, India for the award of Senior Research Fellowship to AAA.

## References

- Bradshaw, T. D., Wrigley, S. Shi, D. F. Schultz, R. J., Paull, K. D. & Stevens, M. F. (1998). *Br. J. Cancer*, **77**, 745–752.
- Bs, H., Akberali, P. M. & Shivananda, M. K. (1996). *Boll. Chim. Farm.* **135**, 447–451.
- Cox, O., Jackson, H., Vargas, V., Baez, A., Colon, J. I., Gonzalez, B. C. & De Leon, M. (1982). *J. Med. Chem.* **25**, 1378–1381.
- Crofton, K. M. (1996). *Toxicol. Lett.* **84**, 155–159.
- Dash, G., Patra, M. & Praharaj, S. (1980). *Indian J. Chem. Ser. B*, **19**, 894–897.
- Dögruer, D. S., Unlü, S., Sahin, M. F. & Ye Silada, E. (1998). *Farmaco*, **53**, 80–84.
- Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
- Ergen, C. N., Ulusoy, N., Capan, G., Sains, G. O. & Kiraz, M. (1996). *Arch. Pharm. (Weinheim, Ger.)*, **329**, 427–430.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Frenz, B. A. (1978). *The Enraf–Nonius CAD-4 SDP – a Real-Time System for Concurrent X-ray Data Collection and Crystal Structure Solution. Computing in Crystallography*, edited by H. Schenk, R. Olthof-Hazekamp, H. van Koningsveld and G. C. Bassi, pp. 64–71. Delft University Press.
- Gülerman, N., Rollas, S., Kiraz, M., Ekinç, A. C. & Vidin, A. (1997). *Farmaco*, **52**, 691–695.
- Habib, N. S., Soliman, R., Ashour, F. A. & El-Taiebi, M. (1997). *Pharmazie*, **52**, 844–847.
- Invidiata, F. P., Simoni, D., Scintu, F. & Pinna, N. (1996). *Farmaco*, **51**, 659–664.
- Jayanthi, G., Muthusamy, S., Paramasivam, R., Ramakrishnan, V. T., Ramasamy, N. K. & Ramamurthy, P. (1997). *J. Org. Chem.* **62**, 5766–5770.
- Muir, J. A., Gomez, G. M., Muir, M. M., Cox, O. & Cadiz, M. E. (1987). *Acta Cryst. C* **43**, 1258–1261.
- Naito, Y., Akahoshi, F., Takeda, S., Okada, T., Kajii, M., Nishimura, H., Sugiura, M., Fukaya, C. & Kagitani, Y. (1996). *J. Med. Chem.* **39**, 3019–3029.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Puviarasan, K., Govindasamy, L., Shanmuga Sundara Raj, S., Velmurugan, D., Jayanthi, G. & Fun, H.-K. (1999). *Acta Cryst.* **C55**, 948–951.
- Sheldrick, G. M. (1997). *SHELXS97 and SHELXL97*. University of Göttingen, Germany.
- Tada, S., Hatano, M., Nakayama, Y., Volrath, S., Guyer, D., Ward, E. & Ohta, D. (1995). *Plant Physiol.* **109**, 153–159.